These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP). Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207 [TBL] [Abstract][Full Text] [Related]
7. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol. Mallah N; Ares-Gómez S; Pardo-Seco J; Malvar-Pintos A; Santiago-Pérez MI; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; González-Pérez JM; Rodríguez-Tenreiro C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F Hum Vaccin Immunother; 2024 Dec; 20(1):2348135. PubMed ID: 38738683 [TBL] [Abstract][Full Text] [Related]
8. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. López-Lacort M; Muñoz-Quiles C; Mira-Iglesias A; López-Labrador FX; Mengual-Chuliá B; Fernández-García C; Carballido-Fernández M; Pineda-Caplliure A; Mollar-Maseres J; Shalabi Benavent M; Sanz-Herrero F; Zornoza-Moreno M; Pérez-Martín JJ; Alfayate-Miguelez S; Pérez Crespo R; Bastida Sánchez E; Menasalvas-Ruiz AI; Téllez-González MC; Esquiva Soto S; Del Toro Saravia C; Sanz-Muñoz I; Eiros JM; Matías Del Pozo V; Toquero-Asensi M; Pastor-Villalba E; Lluch-Rodrigo JA; Díez-Domingo J; Orrico-Sánchez A Euro Surveill; 2024 Feb; 29(6):. PubMed ID: 38333937 [TBL] [Abstract][Full Text] [Related]
9. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312 [TBL] [Abstract][Full Text] [Related]
10. Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain. Zornoza Moreno M; Pérez Martín JJ; Moreno MCG; Abellán MPR Hum Vaccin Immunother; 2024 Dec; 20(1):2357439. PubMed ID: 38857859 [TBL] [Abstract][Full Text] [Related]
11. Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study. López-Lacort M; Corberán-Vallet A; Santonja FJ; Muñoz-Quiles C; Díez-Domingo J; Orrico-Sánchez A J Infect Public Health; 2024 Aug; 17(8):102492. PubMed ID: 39002465 [TBL] [Abstract][Full Text] [Related]
12. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017 [TBL] [Abstract][Full Text] [Related]
14. Paediatric intensive care admissions for respiratory syncytial virus bronchiolitis in France: results of a retrospective survey and evaluation of the validity of a medical information system programme. Soilly AL; Ferdynus C; Desplanches O; Grimaldi M; Gouyon JB Epidemiol Infect; 2012 Apr; 140(4):608-16. PubMed ID: 21733254 [TBL] [Abstract][Full Text] [Related]
16. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN; N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500 [TBL] [Abstract][Full Text] [Related]
17. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. Prais D; Danino D; Schonfeld T; Amir J Chest; 2005 Oct; 128(4):2765-71. PubMed ID: 16236953 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case-control study. Lassoued Y; Levy C; Werner A; Assad Z; Bechet S; Frandji B; Batard C; Sellam A; Cahn-Sellem F; Fafi I; Lenglart L; Aupiais C; Basmaci R; Cohen R; Ouldali N Lancet Reg Health Eur; 2024 Sep; 44():101007. PubMed ID: 39139197 [TBL] [Abstract][Full Text] [Related]